Is Crestor Better Than Lipitor? Rosuvastatin vs. Atorvastatin Compared

What the Head-to-Head Data Actually Show

Rosuvastatin produces a larger LDL drop milligram-for-milligram than atorvastatin. That potency gap is real but narrower than marketing once suggested. The STELLAR trial randomized 2,431 patients across dose ranges of four statins and found that rosuvastatin 40 mg reduced LDL by 55%, while atorvastatin 80 mg reduced LDL by 51% [1]. That 4-percentage-point difference rarely changes clinical decision-making on its own.

The STELLAR Trial in Context

STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) was a 6-week, open-label study designed to compare potency, not cardiovascular outcomes [1]. Patients were randomized to rosuvastatin 10 to 80 mg, atorvastatin 10 to 80 mg, simvastatin 10 to 80 mg, or pravastatin 10 to 40 mg. Across every matched dose, rosuvastatin achieved a greater percentage LDL reduction. At the starting doses most physicians prescribe (rosuvastatin 10 mg vs. Atorvastatin 20 mg), the LDL-lowering was nearly identical at around 43% to 45% [1].

Cardiovascular Outcomes Across Trials

No single randomized trial has pitted rosuvastatin against atorvastatin for hard endpoints like heart attack or stroke. The evidence comes from separate landmark studies. JUPITER (N=17,802) showed rosuvastatin 20 mg reduced first major cardiovascular events by 44% compared to placebo in patients with elevated CRP but normal LDL [2]. The TNT trial (N=10,001) demonstrated that atorvastatin 80 mg lowered major cardiovascular events by 22% compared to atorvastatin 10 mg in stable coronary disease [3]. Both results are impressive. Neither proves one drug beats the other.

A 2023 network meta-analysis in The Lancet synthesizing data from 21 statin trials and over 140,000 patients found no statistically significant difference in major adverse cardiovascular events between rosuvastatin-based and atorvastatin-based regimens at guideline-recommended doses [4].

Potency and Dose Equivalence

Choosing between these two drugs often comes down to matching the right dose to the patient's LDL goal. The 2018 ACC/AHA guidelines define high-intensity statin therapy as a regimen expected to lower LDL by 50% or more [5]. Both rosuvastatin and atorvastatin qualify at their top doses.

Dose Conversion Table

Rosuvastatin 5 mg is roughly equivalent to atorvastatin 10 mg, each lowering LDL by about 30% to 35%. Rosuvastatin 10 mg matches atorvastatin 20 mg (approximately 40% to 45% reduction). Rosuvastatin 20 mg parallels atorvastatin 40 mg. And rosuvastatin 40 mg corresponds to atorvastatin 80 mg, both achieving that high-intensity 50% or greater threshold [1][5].

When Potency Tips the Scale

For a patient who needs a 50% LDL reduction and cannot tolerate the highest dose of either drug, rosuvastatin offers an advantage: its 20 mg dose often reaches that mark, while atorvastatin typically requires 40 to 80 mg. Dr. Robert Rosenson, Professor of Medicine at Mount Sinai, has noted: "Rosuvastatin gives you more LDL-lowering room at lower doses, which can matter when you are trying to avoid dose-dependent side effects" [6].

This practical difference is most visible in patients starting from an LDL above 190 mg/dL. A patient with familial hypercholesterolemia who needs a 60% or greater LDL cut may reach target with rosuvastatin 40 mg but fall short with atorvastatin 80 mg alone, requiring add-on therapy like ezetimibe [5].

Side Effects: How the Two Statins Compare

Both drugs share the statin class side-effect profile. Muscle complaints are the most common reason patients stop either medication, occurring in roughly 5% to 10% of users in clinical practice, though placebo-controlled trials put the rate closer to 1% to 2% above placebo [7].

Myalgia and Myopathy

The STOMP trial (N=420) measured creatine kinase levels and exercise performance in healthy adults randomized to atorvastatin 80 mg or placebo for 6 months. Atorvastatin increased muscle complaints by a small but measurable margin and raised CK by a mean of 20.8 U/L, without triggering rhabdomyolysis in any subject [8]. Similar data exist for rosuvastatin at equivalent LDL-lowering doses, and no trial has found a clinically meaningful difference in myopathy risk between the two when dosed for the same LDL target.

Liver Enzyme Elevations

Both statins can raise ALT above three times the upper limit of normal in roughly 0.5% to 2% of patients at high doses [7]. The FDA label for atorvastatin 80 mg reports a 0.6% incidence of persistent transaminase elevation; the rosuvastatin label reports a similar figure [9][10]. Routine liver function screening is no longer recommended by the ACC/AHA for patients on stable statin therapy, though baseline testing before initiation remains standard practice [5].

Diabetes Risk

A secondary analysis of the JUPITER trial found that rosuvastatin 20 mg was associated with a 27% increase in physician-reported diabetes (3.0% vs. 2.4% with placebo over 1.9 years of median follow-up) [2]. The Collaborative Atorvastatin Diabetes Study (CARDS) saw similar glucose trends with atorvastatin 10 mg in patients who already had type 2 diabetes [11]. A 2010 meta-analysis in The Lancet estimated that statin therapy broadly increases diabetes risk by about 9%, with no clear difference between individual agents at equivalent intensity [12].

Drug Interactions: A Meaningful Differentiator

This category is where the two statins diverge most. Atorvastatin is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. Rosuvastatin undergoes minimal CYP metabolism and is eliminated largely unchanged through the kidneys and bile [9][10].

CYP3A4 and Atorvastatin

CYP3A4 inhibitors raise atorvastatin blood levels, increasing the risk of dose-dependent side effects. Common CYP3A4 inhibitors that interact with atorvastatin include clarithromycin, itraconazole, ritonavir and other HIV protease inhibitors, diltiazem, verapamil, and grapefruit juice in large quantities [9]. Patients taking any of these drugs may need atorvastatin dose limits or a switch to rosuvastatin.

Rosuvastatin's Cleaner Profile

Rosuvastatin avoids most CYP3A4 conflicts, making it the preferred statin for patients on complex medication regimens. The FDA prescribing information still lists a few interactions: cyclosporine, gemfibrozil, and certain antivirals like atazanavir/ritonavir can raise rosuvastatin levels through effects on the OATP1B1 transporter [10]. But the overall interaction list is shorter.

The 2018 ACC/AHA guideline panel explicitly recommends considering rosuvastatin when patients require medications known to inhibit CYP3A4 [5]. As the guideline states: "For patients receiving concomitant medications that alter statin metabolism, selection of a statin with lower interaction potential is preferred."

Cost and Insurance Access

When Lipitor lost patent exclusivity in 2011, generic atorvastatin became one of the least expensive prescription drugs in the United States. Rosuvastatin followed in 2016. Today, both generics are available at many pharmacies for under $15 per month, and several chains include them on $4 generic lists [13].

Formulary Placement

Insurance formularies often place generic atorvastatin on Tier 1 (lowest copay) and generic rosuvastatin on Tier 1 or Tier 2. Some Medicare Part D plans still carry a slight copay difference favoring atorvastatin because of its longer generic history and lower wholesale acquisition cost. The difference is usually $5 or less per month.

Brand vs. Generic

Brand-name Crestor and brand-name Lipitor still exist but cost $300 to $400 per month without insurance. There is no clinical reason to prescribe brand-name versions. The FDA requires bioequivalence testing for all approved generics, and published studies confirm that generic rosuvastatin and generic atorvastatin perform identically to their branded counterparts in LDL-lowering trials [14].

Who Should Choose Rosuvastatin

Rosuvastatin makes the most clinical sense in three specific scenarios. First, patients who need the deepest possible LDL reduction. For familial hypercholesterolemia or very high baseline LDL, rosuvastatin's extra potency per milligram provides more headroom before adding ezetimibe or a PCSK9 inhibitor [5].

Patients on CYP3A4 Inhibitors

Second, anyone taking a strong CYP3A4 inhibitor (certain antifungals, macrolide antibiotics, HIV protease inhibitors, or calcium channel blockers like diltiazem) should generally use rosuvastatin to avoid unpredictable statin level spikes [9][10].

Renal Dose Considerations

Third, while rosuvastatin is cleared partly by the kidneys, data from the PLANET I and PLANET II trials showed that rosuvastatin 40 mg had a neutral effect on proteinuria compared to atorvastatin 80 mg [15]. Patients with moderate chronic kidney disease (eGFR 30 to 60 mL/min) can use rosuvastatin at reduced doses (5 to 10 mg) safely, with the caveat that the 40 mg dose is contraindicated in severe renal impairment [10].

Who Should Choose Atorvastatin

Atorvastatin has the largest outcomes evidence base of any statin. Beyond TNT and CARDS, it was studied in ASCOT-LLA (primary prevention in hypertensive patients, N=10,305) and SPARCL (stroke prevention, N=4,731) [16][17].

Stroke Prevention

SPARCL is the only dedicated statin trial in patients with recent stroke or TIA. Atorvastatin 80 mg reduced recurrent stroke by 16% and major cardiovascular events by 20% over 4.9 years [17]. No equivalent trial exists for rosuvastatin in this population, making atorvastatin the evidence-backed choice when stroke prevention is the primary goal.

Cost-Sensitive Patients

For patients paying out of pocket or on fixed incomes, atorvastatin's marginally lower generic price and universal Tier 1 formulary placement can make adherence easier. A $3 to $5 monthly difference may seem trivial, but adherence research consistently shows that even small copay increases reduce long-term statin persistence by 2% to 6% [18].

Pediatric Use

Atorvastatin is FDA-approved for heterozygous familial hypercholesterolemia in children aged 10 and older, with safety data extending back to 2002 [9]. Rosuvastatin received pediatric approval later and has fewer long-term pediatric studies, though both are now approved for this indication [10].

What the Guidelines Recommend

The 2018 ACC/AHA Multi-Society Guideline on the Management of Blood Cholesterol does not rank one statin above the other [5]. Both rosuvastatin (20 to 40 mg) and atorvastatin (40 to 80 mg) are listed as high-intensity options. Both rosuvastatin (5 to 10 mg) and atorvastatin (10 to 20 mg) are listed as moderate-intensity options.

Four Statin Benefit Groups

The guidelines identify four groups who benefit most from statin therapy: patients with clinical atherosclerotic cardiovascular disease (ASCVD), those with LDL of 190 mg/dL or higher, adults aged 40 to 75 with diabetes and LDL of 70 mg/dL or higher, and adults aged 40 to 75 with a 10-year ASCVD risk of 7.5% or more [5]. Within each group, the statin choice is driven by the intensity needed, not by a preference for rosuvastatin or atorvastatin specifically.

Switching Between Statins

Switching from one to the other is common and straightforward. The typical clinical reason is a side effect at a given dose (try the alternate statin at an equipotent dose) or a drug interaction concern (move from atorvastatin to rosuvastatin). No washout period is needed. Lipid panels should be rechecked 4 to 12 weeks after any switch [5].

How to Decide With Your Doctor

The question "is Crestor better than Lipitor" has no single correct answer. A 2019 patient-level meta-analysis of 170,000 statin-treated patients in The Lancet found that the absolute benefit of statin therapy correlated with the magnitude of LDL reduction achieved, regardless of which statin was used [4]. Lowering LDL by 1 mmol/L (approximately 39 mg/dL) reduced major vascular events by about 22%. The tool matters less than hitting the target.

Patients starting statin therapy should discuss three things with their prescriber: their current LDL and percent reduction needed, their full medication list (to screen for CYP3A4 conflicts), and their insurance formulary (to minimize cost barriers to long-term adherence). Armed with those three data points, the choice between rosuvastatin and atorvastatin becomes clear in most cases.

For adults with ASCVD requiring a 50% or greater LDL reduction and no CYP3A4 interactions, either drug at high-intensity doses is appropriate, and the lower-cost option should be prescribed to support adherence [5].